We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

AVXL Anavex Life Sciences Corporation

0.00 (0.0%)
Pre Market
Last Updated: 03:08:46
Delayed by 15 minutes


Draw Mode:

Volume 0
Bid Price 7.90
Ask Price 8.49
News -
Day High


52 Week Range


Day Low
Share Name Share Symbol Market Stock Type
Anavex Life Sciences Corporation AVXL NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.00 0.0% 8.01 03:08:46
Open Price Low Price High Price Close Price Previous Close
Trades Shares Traded Average Volume 52 Week Range
0 0 - 4.90 - 11.925
Last Trade Type Quantity Price Currency
- 0 US$ 8.01 USD

Anavex Life Sciences (AVXL) Options Flow Summary

Overall Flow


Net Premium


Calls / Puts


Buys / Sells




Sweeps Ratio


Anavex Life Sciences Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
657.51M 82.09M - 0 -47.51M -0.58 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Anavex Life Sciences News

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No AVXL Message Board. Create One! See More Posts on AVXL Message Board See More Message Board Posts

Historical AVXL Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week7.278.327.017.781,077,7420.7410.18%
1 Month5.988.325.476.791,171,1662.0333.95%
3 Months7.988.38994.906.501,049,7240.030.38%
6 Months9.0710.174.907.43953,493-1.06-11.69%
1 Year8.3811.9254.908.441,048,085-0.37-4.42%
3 Years4.9031.504.63813.071,479,8933.1163.47%
5 Years2.2131.501.2510.881,160,3365.80262.44%

Anavex Life Sciences Description

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2.

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 |